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Patrick Michl1 and Sebastian Krug1*Abstract
Background: Paraneoplastic neurological syndromes (PNS) have frequently been described in patients with lung or
breast cancer. However, some reports also described a correlation to carcinoid tumors, probably triggered via the
excessive release of hormones.
Case presentation: We report the case of a 40-year-old woman that was diagnosed with a neuroendocrine
neoplasm (NEN) of the rectum and multiple synchronous liver metastases ten years ago. She initially responded
well to transarterial chemoembolization (TACE), resulting in prolonged disease stabilization. However, ten years after
initial diagnosis the patient developed unspecific neurological symptoms that could not be classified by standard
neurological diagnostic work-up. Special laboratory analysis revealed a high titer of anti-Ri (ANNA-2), a
well-characterized antibody that is associated with paraneoplastic neurologic syndromes. The patient’s symptoms
improved markedly after a 5-day-course of high-dose glucocorticoid therapy. To our knowledge, this is the first
report of a Ri-positive PNS in a patient with hormone-negative rectal NEN.
Conclusion: PNS can complicate the patient’s clinical course, response to treatment, impact prognosis and even be
interpreted as metastatic spread. However, owing to their rarity, the knowledge of these syndromes is very helpful
in order to be able to provide evidence-based diagnostic and therapeutic approaches.
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Neuroendocrine Neoplasms (NENs) of the rectum have
been increasing in incidence over the last decades and
now comprise 16% of all NENs [1]. Most rectal NENs
are localized at diagnosis with acceptable 5-year overall
survival rates of approximately 90%. However, regional
and distant disease is associated with a dramatically im-
paired outcome. Factors influencing survival included
tumor size, histology, proliferation index, depth of inva-
sion and lymphvascular invasion [2]. Localized tumors
that are small (T1 and <1-2 cm of size) can be managed
with endoscopic resection. For advanced disease the
benefit of radical surgery remains to be elucidated [3].* Correspondence: krugs@med.uni-marburg.de
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unless otherwise stated.So far, no published data on treatment outcomes for the
metastatic situation are existing, therefore, multidiscip-
linary treatment options should be included into consid-
erations [2].
Paraneoplastic neurological syndromes (PNS) are mainly
associated with lung cancer, gynecological tumors and
hematological diseases. The expression of antigens by vari-
ous neoplasms lead to antibody formation that may induce
an intrathecal inflammatory process leading to distinct
neurological symptoms [4,5]. Moreover, specific antigen
recognition of antibodies in neuronal tissue induces char-
acteristic neurological symptoms. There are few cases de-
scribing concomitant neurological symptoms in patients
with neuroendocrine neoplasms, however, mostly due to
excessive hormone release and seldomly correlated to posi-
tive antibodies [6]. This report represents the first case of
an anti-Ri positive paraneoplastic brainstem encephalitis ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neuroendocrine rectum neoplasm.
Case presentation
A 40-year old woman was referred to our clinic in 2003
after detection of multiple lesions in both hepatic lobes
during routine ultrasound examination. The patient did
not report weight loss, night sweats or fever. She had no
flush symptoms or diarrhea, only a slight postprandial dis-
comfort in the right upper quadrant. Apart from a moder-
ate hepatomegaly, physical examination was unremarkable.
Routine laboratory findings were within normal limits
without indication of liver disease or advanced malignancy.
Likewise, chromogranin A, serotonin and 5-HIAA were
within normal range. Sonographically the lesions were of
high echogenicity with a hypoechoic halo. The largest le-
sion found in segment VI had a diameter of 6.8 cm. Mul-
tiple additional hepatic lesions were spread throughout
both lobes with a size of approximately 1 cm. A CT-guided
core biopsy was performed to establish histopathological
diagnosis. Histological analysis of the biopsy material
showed a G1 neuroendocrine neoplasm (NEN) with a low
proliferation rate (Ki-67 < 1%) (Figure 1a-d).
For tumor staging, abdominal imaging by MRI and a
chest CT scan were performed which confirmed multiple
bilobular hepatic lesions with no option for complete
surgical removal. Somatostatin receptor scintigraphy
(SRS) showed a positive receptor status of the hepaticFigure 1 Immunohistochemical characteristics of primary and liver m
formation pattern of neuroendocrine tumor cells of solid nests of regular c
Mitotic cells are absent (a). The proliferation rate is very low, Ki67 marks les
immunohistochemical reaction for chromogranin A and synaptophysin is a
rectum polyp exhibits the same histological (e) and immunohistochemical
neuroendocrine markers chromogranin A and synaptophysin (g and h).lesions. Colonoscopy identified the primary tumor in the
rectum: 5 cm from the anus a polyp with 1 cm diameter
was found and endoscopically removed by snare biopsy.
Microscopical analysis confirmed a G1 NEN with similar
histological appearance as seen in the hepatic metastases
(Figure 1e-h). Due to the positive somatostatin (SMS) re-
ceptor status treatment with octreotide was started.
6 months later, however, a restaging revealed progression
of the liver metastases. As there was no evidence of extra-
hepatic manifestation we decided to perform a transarter-
ial chemoembolization (TACE) of the hepatic lesions. The
patient received in total 7 TACE interventions without
complications over a period of 2 years. Over a follow-up
period of 7 years without further anti-cancer therapy up
to the present, MRI revealed stable disease according to
RECIST criteria.
In 2013, however, the patient presented to the general
practitioner with hoarseness as well as tenderness on pal-
pation and stabbing pain in the right lower jaw, the man-
dibular joint and the right part of the tounge. During the
course of several weeks, additional symptoms like palsy of
the tongue and dysarthria emerged and the patient was
put on an empiric antibiotic treatment with a cephalos-
porine. With increasing numbness of the tongue and
on the inner surface of the cheek, pain of the tongue,
worsening dysarthria and dysphagia the patient pre-
sented to the emergency department of our hospital. A
thorough neurological examination including cranialetastases. The initial liver biopsy shows the characteristic cell
ells with broad eosinophilic cytoplasm and small inconspicuous nuclei.
s than 1% of the tumor cell nuclei (b). Furthermore, the strong
solid proof for neuroendocrine differentiation (c and d). Likewise the
features including low proliferation (f) and marked reaction for the
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a time of flight (TOF)-imaging as well as ENT examin-
ation was not instrumental to establish a diagnosis.
However, a lumbar cerebrospinal fluid (CSF) puncture
revealed a pleocytosis (19 cells/μl) as well as an intra-
thecal protein synthesis (IgG), both in accordance with an
inflammatory process in the brain. Unremarkable CSF pa-
rameters included negative PCR’s for herpes simplex I and
II virus, Epstein Barr virus, cytomegalovirus, varicella zos-
ter and toxoplasma as well as negative bacterial cultures,
cryptococcus antigen, and cytology examination for malig-
nant cells. Transcranial magnetic stimulation showed an
increased latency between the primary motor cortex and
the left arm, whereas the right arm and both legs showed
normal conduction. Serologic investigation of onconeural
antibodies showed a highly positive titer for anti-Ri
(1:2560, normal <80). The positive indirect immunofluor-
escence technique (IIFT) was validated with immunoblot-
ting, which substantiated the isolated presence of the
Ri-antibodies (Figure 2). As a result of this the diagnosis
paraneoplastic brainstem encephalitis was established. An
intravenous methylprednisolone therapy with 500 mg for
5 days led to rapid improvement of the patients neuro-
logical symptoms with concomitant decline of the anti-Ri
titer from 1:2560 to 1:320. On follow-up 3 months after
steroid therapy, the patient is currently completely asymp-
tomatic. A regular methylprednisolone therapy for 5 days
intravenously every 8 weeks is planned over a treatment
period of at least 2 years. Since brainsteam encephalitis
as paraneoplastic neurological syndrom have not been
described in patients with metastatic rectum NENFigure 2 Validation of Ri-antibodies via IIFT and immunoblot assay. C
grey matter of primate cerebellum (upper left). (SM = stratum moleculare; S
plexus myentericus (PM) revealed no binding of Ri-antibodies (upper right)
Lineblot (lower panel) confirmed the IIFT result. No reactivity was observedbefore, other tumors were ruled out including a normal
gynecological examination and a FDG-PET-CT without
evidence for a lung tumor.
Conclusion
Rectum NET
Approximately 5-20% of all gastrointestinal neuroendo-
crine neoplasms (NEN) are localized in the rectum [3,7].
In 50% the diagnosis of a rectal NEN is made upon rou-
tine endoscopy for colorectal cancer screening [8]. More
frequent usage of colonoscopic screening programs
might explain the increasing incidence in recent years.
Most commonly, in 90% of the cases, rectal neuroendo-
crine neoplasms are diagnosed in a localized stage [9].
Metastatic spread is rare at the time of diagnosis, adding
up to 2-10% [2,10,11]. Localized rectal NEN have a 5-
year survival rate of 90%. In contrast, distant metastatic
spread is associated with a 5-year overall survival rate of
30% [9] and a median survival of 22 months [11]. Nega-
tive prognostic factors for malignant behavior are tumor
size, depth of invasion, lymph node involvement and
higher histopathological grading (proliferation rate >2%
and mitotic index ≥ 2/10 HPF) (Table 1) [2,12-14].
Tumor size > 20 mm is associated with elevated risk of
distant metastases and poorer prognosis [3,15]. Lympho-
vascular invasion likely represents another risk factor
[10,12]. Our patient had a well differentiated tumor with a
Ki-67 index of less than 2% and a tumor diameter of less
than 1 cm. None of the above mentioned criteria pre-
dicting malignant behavior were present (Table 1).
Nevertheless the patient was amongst the 5% ofharacteristic granular fluorescence staining of all neurone nuclei of the
G = stratum granulosum; PZ = Purkinje cells). Peripheral neurons of the
. High positive reaction with the recombinant Ri-antigen (Nova1) in
for anti-Hu, anti-Yo, anti-Ma2/Ta, anti-CV2 and anti-amphiphysin.
Table 1 Factors predicting malignant behavior (8, 11)
Predictive factor
Tumor size > than 20 mm
Mitotic index >2/10 high power fields
Muscularis layer invasion –
Lymphovascular invasion –
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with distant hepatic metastasis. The median survival
rate for this patient population averages 22 months.
Our patient remarkably exceeds this median survival
more than 5-fold (Table 2). She clearly benefited from
TACE treatment resulting in disease stabilization for
many years with excellent quality of life until the para-
neoplastic symptoms occurred.Paraneoplastic neurological syndromes
Paraneoplastic syndromes form a heterogeneous group
of complications associated with malignancy that are
caused neither by local effects of the tumor mass or its
metastases, nor by vascular, infectious, or nutritional im-
pairments. In several literature reports, paraneoplastic
syndromes are estimated to occur in approximately 0.01
to 8% of cancer patients [16,17]. The most frequent can-
cer entity associated with paraneoplastic syndromes is
small cell lung cancer [5] followed by breast cancer, gyne-
cologic tumors and hematologic malignancies such as
lymphoma [4]. A paraneoplastic syndrome can affect vari-
ous organs and has been proposed to be caused by two
main pathophysiological mechanisms. First, tumors are
capable of producing a variety of functionally active
peptides that imitate hormone function and lead to a
metabolic disturbance (as in endocrine paraneoplasticTable 2 Epidemiologic data (6)
Incidence
Neuroendocrine tumor 5,25/100.000
Neuroendocrine tumor of the rectum 0,86/100.000
Rectal NET General data (our patient)
Age diagnosis years 56(40)







Distant 22(132)syndromes) [18]. In neurologic paraneoplastic syndromes
it has been described that tumors ectopically express anti-
gens that are normally expressed in the nervous system
which leads to an immune-mediated cross-reactivity
[19,20]. Neurologic PNS may involve any part of the ner-
vous system (central, peripheral or the neuromuscular
junction) [21]. The production of antibodies against tu-
morous antigens is an autoimmune process [22]. The
similarity of tumor antigens to elements of the nervous
system leads to an attack of tumor-directed antibodies
against nerval epitopes. These antibodies are known as
onconeural antibodies and are commonly used in the
diagnostic work-up to diagnose paraneoplastic neuro-
logical syndromes [4]. The diagnostic criteria for a PNS
include the presence of cancer within the next 5 years, the
definition of a classical or non-classical syndrome and the
presence of well-defined onconeural antibodies [23].
Based on the classification in classic and non-classic PNS,
brainsteam encephalitis is affiliated to the non-classic
forms.
There are various cases in the literature describing pa-
tients with neuroendocrine carcinoid tumors and neuro-
logical symptomes with the tumors being localized in
the stomach [24] or the bronchial system [25,26]. In the
majority of these cases the neurological affections were
due to the hormones produced by the carcinoid or by
the metastases [27]. Only a minority of single cases ac-
complish the diagnostic criteria of a PNS (e.g. positive
antibodies). One case of PNS in neuroendocrine tumor
of the rectum has been reported in association with
anti-Hu antibodies [28]. To our knowledge, our case
represents the first describing a non-functional neuroen-
docrine tumor leading to a paraneoplastic neurological
syndrome due to anti-Ri antibodies. The Anti-Ri anti-
body which was found in our case belongs to the group
of antibodies whose strong association to cancer has
been proven. Most commonly this antibody is associated
with breast cancer and small cell lung cancer [6,29].
Typically, jaw dystonia and laryngospasm which were
predominant symptoms of our patient are strongly asso-
ciated with brainstem encephalitis due to Ri antibodies
[30]. There are reports about Anti-Ri associated PNS in
neuroendocrine tumors [25,31] but to the best of our
knowledge none was associated with nonfunctional rec-
tal neuroendocrine tumors. Most effective treatment of
the PNS is tumor specific treatment that is in accord-
ance to the existing treatment guidelines of the tumor
entity [32]. As described in other publications [33], im-
munomodulatory or –suppressive treatment leads to im-
provements of the functional ability of the patient but
does not represent causal therapy. Our patient received
high-dose immunmodulatory therapy and fortunately
showed positive response. After being free from neuro-
logical symptomes the therapy was gradually reduced.
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patient is still stable on follow-up according to imaging
and biochemical means 6 months after the occurrence
of the PNS, so far we have no indication that the PNS
represents an early sign of disease recurrence.
In summary, this report represents the first case of an
anti-Ri positive PNS occurring in a non-functional rectal
NEN. Neurological symptoms in a patient with NEN
should always trigger further work-up to rule out a PNS
also in patients who are long-term clinically stable.
Materials and methods
We retrospectively analyzed a patient with metastasized
neuroendocrine rectum neoplasm treated in our institu-
tion since 2003. This case presentation was conducted in
accordance with the Declaration of Helsinki and with the
approval of the local ethics committee at the University of
Marburg. The evaluation of the patient-related informa-
tion was done with patient informed consent. Tumor tis-
sue was explored immunohistochemically concerning
expression of Chromogranin, Synaptophysin, Ki-67. Ana-
lyses were performed according to a standardized protocol
using Leica-Bond-Max-Autostainer and the antibodies in
the following dilutions: Chromogranin: Dako 1:2000;
Synaptophysin: Dako 1:50; Ki-67: Dako 1:1000. For indir-
ect immunofluorescence technique (IIFT) patient serum
in various dilutions (1:10-1:5120) was incubated with tissue
sections of primate cerebellum, nerve and gut (Neur-
ology Mosaik1, Fa. Euroimmun, Lübeck). Fluorescein-
tagged goat-anti-human-IgAGM detected bound anti-Ri
antibodies. The IIFT was corroborated via immunoblot-
ting. 1.5 ml of serum (dilution 1:101) was incubated with
the following antigen fragments: Amphiphysin, CV2,
PNMA2 (Ma2/Ta), Ri, Yo and Hu (Euroline Profil 2, Fa.
Euroimmun Lübeck). Alkaline phosphatase-labelled goat-
anti-human-IgG served as the enzyme conjugate.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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